KAI-9531

1 paper4 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab

Human trial1

Outcomes

HbA1c

downin humans1

1 study

KAI-9531 decreases HbA1c in humans.
“Greater reductions in fasting glucose, fasting insulin, and HbA1c were observed with KAI-9531 vs PBO.”
Human trial29 daysn = 49
A Phase 1, Randomized, Double-Blind, Single-Ascending Dose Study of KAI-9531, a Novel Dual GLP-1/GIP Receptor Agonist in Development for People Living with Overweight/Obesity
ADA Scientific Sessions 2026 abstract5 Jun 2026

Latest

1 in 12 months

ADA Scientific Sessions 2026 Abstract6 Jun

A Phase 1, Randomized, Double-Blind, Single-Ascending Dose Study of KAI-9531, a Novel Dual GLP-1/GIP Receptor Agonist in Development for People Living with Overweight/Obesity

Randomised trial in 49 peopleOverweight

Paper

KAI-9531

Outcomes

Latest

A Phase 1, Randomized, Double-Blind, Single-Ascending Dose Study of KAI-9531, a Novel Dual GLP-1/GIP Receptor Agonist in Development for People Living with Overweight/Obesity

Related